• Loading stock data...

About Nordicus

Transforming Potential Into Value

Nordicus Partners Corporation is a U.S. publicly traded business accelerator and holding company focused exclusively on empowering Nordic life sciences companies to succeed in the U.S. market.

Founded in 1993 as Cardiotech International, Inc., Nordicus Partners Corporation has evolved into a leading U.S. publicly traded business accelerator and holding company dedicated to empowering Nordic life sciences companies to succeed in the U.S. market. Combining Nordic innovation with U.S. operational expertise, we create a distinct advantage in identifying, scaling, and exiting high-potential companies in high-growth markets with unmet medical needs.

Nordicus Partners advises and invests in Nordic and U.S. life sciences companies, leveraging a diverse team of American and Nordic professionals to deliver exceptional results. Our team, a dynamic blend of Nordic and American professionals, combines diverse perspectives and strategies to create value and drive success for both the companies we support and our investors.

Headquartered in the U.S. and publicly listed on the OTCQB Market under the ticker symbol “NORD,” Nordicus Partners is strategically structured to maximize shareholder value. Our Denmark-based management company, NP Communications A/S, operates as a wholly owned subsidiary, ensuring that none of the shareholders’ investments are used to cover management fees. This structure highlights our commitment to delivering optimal returns while advancing groundbreaking solutions in the life sciences industry.

The NORDICUS Profile

We are targeting transformative and scalable opportunities, eyeing Nordic and U.S. life sciences companies aiming to make a significant impact, but is seeking a companion that can provide optimal conditions for innovators to flourish and getting established on the U.S. market.

Life Sciences